摘要
目的探讨胰高血糖素样多肽-1(GLP-1)类似物利拉鲁肽对不同病程2型糖尿病患者的治疗效果。方法收集11例不同病程血糖控制不佳的2型糖尿病患者,在原治疗基础上加用利拉鲁肽0.6mg qd皮下注射,1周后改为1.2mg qd皮下注射。血糖达标值定为:FBG<7mmol/L,PBG<9mmol/L。血糖达标即依次减磺脲类、胰岛素、拜糖平用量直至停药。每周随访测血糖、血压、体重,每3个月检测肝肾功能、HbA1c、血脂。结果因腹泻不能耐受停用利拉鲁肽者1例,余10例患者中,最终只用利拉鲁肽联合二甲双胍治疗者3例;减少口服药物种类者2例;减少胰岛素用量者3例,余2例患者血糖亦有不同程度的下降。所有患者体重下降,血压、血脂、HbA1c均有改善。结论利拉鲁肽在使2型糖尿病患者血糖达标的同时,降低患者体重、血压,对短病程患者效果更明显,能改善胰岛细胞功能,低血糖发生率低。
Objective To investigate the effects of glucagon like peptide-1(GLP-1) analogues Lilalu peptide on different course of disease in patients with type 2 diabetes treatment effect.Methods 11 patients with different course of disease and poor glycemic control in patients with type 2 diabetes,in the original treatment combined with Liraru peptide 0.6 mg QD subcutaneous injection,a week later renamed 1.2mg QD subcutaneous injection.Glucose standard value set for:FBG<7 mmol/L,PBG<9 mmol/L.Glucose standards that are reducing sulfonylurea,insulin,acarbose dosage until withdrawal.Weekly follow-up measurement of blood glucose,blood pressure,body weight,every 3 months for liver and kidney function,HbA1c,blood lipid.Results Diarrhea due to intolerance to deactivate the Lilalu peptide in 1 cases,more than 10 patients,ultimately only Lilalu peptide combined with metformin in treatment of 3 cases of oral drug type;reduction in 2 cases;reduce insulin dosage in 3 cases,2 cases with blood sugar also have varying degrees of decline.All patients decreased body weight,blood pressure,blood lipid,HbA1c was improved.Conclusion Lilalu peptide in type 2 diabetes blood sugar standards at the same time,reduce the body weight,blood pressure on patients with a short course of disease,patient effect is more apparent,can improve islet beta cell function,lower incidence of hypoglycemia.
出处
《中外医疗》
2012年第28期101-102,共2页
China & Foreign Medical Treatment
